Protein Restriction for Health & Longevity - Quick Reference Sheet

Protein Restriction for Health & Longevity

Created on 07/26/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Deliberately lowering dietary protein quiets the body's growth signals. It reliably lowers a key growth-promoting hormone and improves blood-sugar and metabolic markers, and its firmest benefit is slowing kidney disease. Favoring plant over animal protein tracks with modestly lower death rates. But past about age sixty-five it accelerates muscle loss and frailty, and may raise the risk of dying. (Full Review)

Protocol

Continuous
~0.8 g/kg/day
Near baseline allowance; emphasize plant sources
Source-Targeted
Limit methionine
Cut red meat, poultry, fish, eggs, dairy; favor legumes
Periodic
0.3–0.4 g/kg/day
~5 days every 1–3 months; normal eating between
Time to effect
IGF-1 reduction
Days–weeks
Growth-signaling hormone declines
Metabolic markers
1–3 weeks
Fasting glucose and insulin sensitivity shift
Longevity benefit
Unmeasurable
Long-term effects not detectable short-term

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Infants, children, and adolescents
  • Frail or sarcopenic older adults
  • Cancer-associated wasting
  • Recovery from major surgery, trauma, burns, or serious infection
  • Dialysis-dependent kidney disease (target ≥1.2 g/kg/day)
  • History of eating disorders
  • BMI below ~18.5
  • Acute catabolic illness
Key Interactions
  • Resistance and endurance exercise
  • Leucine and BCAA supplements
  • Protein powders (whey, casein, collagen, plant isolates)
  • Diabetes medications (insulin, glipizide, glyburide)
  • OTC NSAIDs (ibuprofen, naproxen) and antacids/PPIs (omeprazole)
  • mTOR-inhibiting drugs (rapamycin/sirolimus)
  • Ketoanalogue supplements (in kidney disease)

Risk & Side Effects

  • High: Loss of muscle mass and sarcopenia; protein-energy malnutrition and wasting
  • Medium: Increased mortality in older adults; impaired immune function and wound healing; reduced bone mineral density
  • Low: Blunted anabolic response to exercise
  • Speculative: Micronutrient deficiencies

Monitoring

Marker Target Why
IGF-1 Mid-to-lower age-adjusted reference range Primary target; tracks growth-signaling load
eGFR >90 mL/min/1.73m² Detects kidney impairment that changes the risk-benefit balance
BUN ~7–18 mg/dL Reflects protein/nitrogen load and kidney handling
Serum albumin 4.0–5.0 g/dL Guards against protein-energy malnutrition
Fasting insulin 2–6 µIU/mL Tracks the metabolic/insulin-sensitivity benefit
HbA1c <5.4% Reflects longer-term glucose control
hs-CRP <1.0 mg/L Tracks systemic inflammation, which restriction may lower

Cadence: Baseline, then ~4–8 weeks after starting, then every 3–6 months; more frequent in older adults or kidney disease

Qualitative Assessment

  • Strength and physical function
  • Energy levels
  • Body composition feel
  • Recovery and healing
  • Cognitive clarity and mood